An Observational Study Evaluating the Safety and Efficacy of the Treatment With Biphasic Insulin Aspart (NovoMix 30 FlexPen) [Insulin-aspart/insulin-protamine-aspart] in the Treatment of Type 2 Diabetics After Failing on Basal/ Intermediate Mono or Combination Therapy.
Phase of Trial: Phase III
Latest Information Update: 09 Mar 2016
At a glance
- Drugs Insulin aspart/insulin protamine aspart (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 31 Aug 2018 Biomarkers information updated
- 17 Dec 2009 Actual end date changed from Jun 2009 to May 2009 as reported by ClinicalTrials.gov.
- 08 Jul 2009 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.